This portfolio primarily directs its capital, dedicating a minimum of 80% of its total assets, towards equity holdings—chiefly common shares—of companies operating within the health sciences and closely related sectors. This comprehensive category includes businesses involved in medical equipment and supplies, healthcare service provision, biotechnology, and pharmaceutical research and manufacturing. The fund maintains a focused investment approach, ensuring that more than a quarter (over 25%) of its assets are committed to these health sciences industries.